Google
ELUT Stock Price & Analysis — Elutia Inc. (Healthcare >> Medical Devices)
ELUT FAQ
What is ELUT's P/E ratio?
Elutia Inc. (ELUT) currently trades at a P/E ratio of 0.54.
What is ELUT's ROE?
Elutia Inc. reports a Return on Equity (ROE) of 221.26%.
What is ELUT's dividend yield?
Elutia Inc. offers a dividend yield of 0.00%.
What is ELUT's Quality Score?
Our AI rates ELUT's overall financial quality at 69 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ELUT?
Our AI Timing Score for ELUT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ELUT belong to?
Elutia Inc. is classified under the Healthcare >> Medical Devices sector on the NASDAQ exchange
ELUT AI Analysis Summary
Our AI summary for ELUT: Elutia Inc. (NASDAQ), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 0.54, ROE of 221.26%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.87
Price
0.01
(1.18%)
Day Change
|
|
|---|
ELUT, the overall quality is ok ( Quality = 69) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
Acceleration of ROE growth rate is below our criteria.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are good , financial health is not good , and ability to make profit is good , ...
| Quality Factors |
|
70% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
12
GREAT
|
| Magic Formula Rank by ROE |
12
GREAT
|
| Magic Formula Rank by ROIC |
14
GREAT
|
| Price | 0.87 |
| PBV / Sector |
1.68 / -101.53
|
| Earning Per Share | 1.14 |
| PE / Sector |
0.54 / 31.42
GREAT
|
| PEG or PE/Growth / Sector |
-0.01 / 0.35
|
| Average 1M Daily Value |
0.09 M
GREAT
|
| Average 1W Daily Value |
0.06 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
72% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-04 08:01:27 |
| Symbol | ELUT |
| Name | ELUTIA INC. |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 44.21 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 37.88 / 20,008.89 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 20 Firstfield Road, Gaithersburg, MD, United States, 20878
Phone: 240 247 1170
Website: https://elutia.com
Sector: Healthcare >> Medical Devices
Description: Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
